Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- V
- W
- X
- Y
- Z
- І
- А
- Б
- В
- Г
- Д
- Е
- Ж
- З
- И
- К
- Л
- М
- Н
- О
- П
- Р
- С
- Т
- У
- Ф
- Х
- Ц
- Ч
- Ш
- Щ
- Э
- Ю
- Я
- Весь список
Warning: mb_strpos(): Empty delimiter in /var/www/u1363561/data/www/biotech.spb.ru/wp-content/plugins/code-snippets/php/snippet-ops.php(581) : eval()’d code(4) : eval()’d code on line 13
K Margolin, S J Forman
Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancyCancer J Sci Am. 2000 Feb;6 Suppl 1:S33-8.
K R Meehan, U N Verma, R Cahill, S Frankel, E M Areman, R A Sacher, R Foelber, C Rajagopal, E A Gehan, M E Lippman, A Mazumder
Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlatesBone Marrow Transplant. 1997 Oct;20(8):643-51.
K Shimizu, R C Fields, B G Redman, M Giedlin, J J Mulé
Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2Cancer J Sci Am. 2000 Feb;6 Suppl 1:S67-75.
K van Besien, K Margolin, R Champlin, S Forman
Activity of interleukin-2 in non-Hodgkin’s lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cellsCancer J Sci Am. 1997 Dec;3 Suppl 1:S54-8.
Kajiyama Y1, Umezu-Goto M, Kobayashi N et al.
IL-2-induced IL-9 production by allergen-specific human helper T-cell clones.Int Arch Allergy Immunol. 2007;143 Suppl 1:71-5. Epub 2007 May 1.
Kawakami Y, Nakamura-Wakatsuki T, Yamamoto T.
Seborrheic dermatitis-like eruption following interleukin-2 administration.Dermatol Online J. 2010 Sep 15;16(9):12.
Keirstead N., Bertinetti-Lapatki C., Knapp D. et al.
Temporal Patterns of Novel Circulating Biomarkers in IL-2-mediated Vascular Injury in the Rat.Toxicol Pathol. 2015 Oct;43(7):984-94. doi: 10.1177/0192623315601245. Epub 2015 Sep 8.
Khairulina, R. Khasanov R., Kotsenko T., Mironov P.
Roncoleukin® therapy of sepsis in children.
Abstacts book of 5th Sci. Meeting of Europ. Soc. of chemotherapy inf. diseases. S.-Petersburg, 1997. P. 58 (R008).
Kharkevich G., Tsimafeyeu I., Demidov L.
Low dose interleukine-2 (IL-2) in combination with interferon-б (IFN) and 5-fluorouracil (5-FU) for metastatic renal cell carcinoma (MRCC).
21-st Annual EAU Congress. France, 2006. Eur. Urol. Suppl.,2006. Vol. 2. N 5. P.286. Abstr. N 1053.
Kharkevich G.Yu., Demidov L.V., Tsimafeyev I.V.
Low-dose Interleukin-2 (IL-2) in combination with Interferon-б (Ifn) and 5-Fluorouracil (5-Fu) for metastatic renal cell carcinoma (Mrcc).
UICC World Cancer Congress. EDUCATION / ABSTRACT BOOK. USA, Washington, 2006. N 131-3. Р. 410.
Kharkevich G.Yu., Tsimafeyeu I.V., Demidov L.V., Semenkova E.N.
Management of paraneoplastic vasculitis by interleukin-2 in patients with metastatic renal cell carcinoma (MRCC).
UICC World Cancer Congress 2006. EDUCATION / ABSTRACT BOOK. Washington, 2006. Abstr. N 11-41. P. 102.
Kim H., Kwon B., Sin J-I.
Combined Stimulation of IL-2 and 4-1BB Receptors Augments the Antitumor Activity of E7 DNA Vaccines by Increasing Ag-specific CTL Responses.PLoS One. 2013 Dec 31;8(12):e83765. doi: 10.1371/journal.pone.0083765. eCollection 2013.
Kiselevskiy M., Shubina I. , Chikileva I. et al. 
PDF
Pharmaceuticals 2020, 13(8), 166; https://doi.org/10.3390/ph13080166
Kiselevskiy MV., Abdulaev A G., Davydov M M.
Malignant Mesothelioma and Pseudomyxoma.Springer. 2019
Kiselevsky M.V.
Atlas Effectors of anti-tumor immunity Ed. Kiselevsky M.V.
Springer 2008. 156p
Kohler PC, Sondel PM.
The role of interleukin-2 in cancer therapy.Cancer Surv. 1989;8(4):861-73. PMID: 2701732.
Kolitz J.E., George S.L., Benson D.M. Jr. et al.
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.Cancer. 2014 Apr 1;120(7):1010-7.
Kolitz JE, Wong GY, Welte K et al.
Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.J Biol Response Mod. 1988 Oct;7(5):457-72. PMID: 3263471.
Korenevskii A.V., Milyutina Yu.P., Zhdanova A.A. et al. PDF
Mass-Spectrometric Analysis of Proteome of Microvesicles Produced by NK-92 Natural Killer Cells.
Сell Technologies in Biology and Medicine. — No. 2, August. — 2018. — P. 564-571.
Kosmaczewska A., Ciszak L., Swierkot J. et al.
Exogenous IL-2 Controls the Balance in Th1, Th17, and Treg Cell Distribution in Patients With Progressive Rheumatoid Arthritis Treated With TNF-alpha Inhibitors.Inflammation. 2015 Apr;38(2):765-74. doi: 10.1007/s10753-014-9987-x.
Krylov K.M., Pivovarova L.P., Smirnov M.N. et al.
Roncoleukin® in the treatment of severe burned patients.
Abstacts book of 5th Sci. Meeting of Europ. Soc. of chemotherapy inf. diseases. S.-Petersburg, 1997. P. 56 (R004).
Kue-Hsiung HsiehChen-Cheng ChouShiu-Feng Huang
Interleukin 2 therapy in severe atopic dermatitis.Journal of Clinical Immunology . January 1991, Volume 11, Issue 1, pp 22–28.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.